-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Image: Figure 7
.
Effects
of IGF1 gene therapy on microglial activation status.
"Based on our findings, we propose IGF1 gene therapy to delay reproductive aging as a potential strategy
to optimize longevity and combat age-related health problems in women.
"
A new research paper published on the cover of Aging (listed as "Aging (Albany NY)" by Medline/PubMed and "Aging- us" by Web of Science), Volume 14, Issue 21, titled "IGF1 gene therapy in middle-aged female rats delays reproductive senescence.
" through its effects on hypothalamic GnRH and kisspeptin neurons
。 ”
The process of aging is the result of a gradual loss of homeostasis and impairment of bodily functions, including the central nervous system, where the hypothalamus plays a key role
in regulating the mechanisms of aging.
Consequences of aging include the chronic pro-inflammatory environment of the hypothalamus, which leads to a decrease in the secretion of gonadotropin-releasing hormone (GnRH) and impairs the function
of kisspeptin neurons.
In the new study, the researchers analyzed the effects of insulin-like growth factor 1 (IGF1) gene therapy on hypothalamic kisspeptin/GnRH neurons and microglia, which mediate inflammatory processes
associated with the aging process.
"The objective of this study is to investigate the effects
of IGF1 gene therapy on the estrous cycle, kisspeptin and GnRH neurons, and microglia in middle-aged female rats.
"
The results showed that kisspeptin expression was higher in the anterior ventral periventricular (AVPV) nucleus of IGF1 rats, and higher GnRH immunoactivity in the arcuate nucleus and middle bulge region
.
In addition, the number of Iba1+ microglia and MHCII+/Iba1+ in IGF1-treated animals AVPV and arcuate nucleus increased
.
In summary, IGF1 gene therapy maintained the generation of kisspeptin in the AVPV nucleus of middle-aged female rats, induced the release of GnRH in the middle bulge region, and changed the number and reactivity
of microglia.
The researchers believe that IGF1 gene therapy may have a protective effect
against decreased reproductive capacity.
"Based on our findings, we propose IGF1 gene therapy to delay reproductive aging as a potential strategy
to optimize longevity and combat age-related health problems in women.
"